CARM: חוב לטווח קצר של החברה Carisma Therapeutics Inc

The current debt load dynamics provided by the GURU.Markets platform show that the current amount is 0.00. The success of Carisma Therapeutics (CARM) is based on the verification of CAR-M therapy and its alliance with Moderna. The company outsources its manufacturing processes and clinical operations to third-party contractors. Carisma Therapeutics (CARM) is currently scaling CAR-macrophages to develop advanced methods for combating solid tumors.

Liquidity management is critical for the biopharmaceutical sector, where Carisma Therapeutics (CARM) invests in costly immuno-oncology developments. This indicator captures the daily dynamics of working capital repayment and procurement, reflecting the actual cost of maintaining operational activities. An analysis of current borrowings allows investors to determine the balance between default risk and the efficiency of utilizing credit markets to scale the business.